Market Newsdesk

Connection Awarded GSA 2GIT Purchase Agreement

Public Sector Business Secures 2nd Generation Information Technology Award

MERRIMACK, N.H.–(BUSINESS WIRE)–
Connection (PC Connection, Inc.; NASDAQ: CNXN), a leading information technology solutions provider to business, government, healthcare, and education markets, announced today that its public sector subsidiary, Connection Public Sector Solutions, has been awarded one of the GSA’s 2nd Generation Information Technology (2GIT) Blanket Purchase Agreements.

The multi-award contract vehicle covers the purchase of commercial off-the-shelf IT hardware, software, and related services, and is valued at $5.5 billion in total. The contract has a base period of one year, with an additional four one-year options. 2GIT is open to all federal, state, local, regional, and tribal governments. Connection is proud to be one of the 79 awardees.

Tim McGrath, President and Chief Executive Officer of Connection said, “It’s an honor to be awarded the 2GIT contract. Participating in this purchase agreement enables our team to better support the technology needs of our Federal Department of Defense and civilian agency customers and deliver the resources and expertise they need to achieve their mission. I look forward to exceeding the expectations of our valued customers and building on the reputation Connection Public Sector Solutions has earned as a trusted IT provider to government agencies.”

Larry Kirsch, President of Connection Public Sector Solutions stated, “We are committed to serving the needs of our government partners, and securing the 2GIT purchase agreement ensures our team is able to offer these customers greater flexibility and choice through seamless, convenient, and affordable IT procurement. It’s a privilege to be selected for the contract, and we will use this opportunity to showcase Connection’s expertise and dedication to exceptional customer service.”

About Connection

PC Connection, Inc. and its subsidiaries, dba Connection, (www.connection.com; NASDAQ: CNXN) is a Fortune 1000 company headquartered in Merrimack, NH. With offices throughout the United States, Connection delivers custom-configured computer systems overnight from its ISO 9001:2015 certified technical configuration lab at its distribution center in Wilmington, OH. In addition, the Company has over 2,500 technical certifications to ensure that it can solve the most complex issues of its customers. Connection also services international customers through its GlobalServe subsidiary, a global IT procurement and service management company. Investors and media can find more information about Connection at http://ir.pcconnection.com.

Connection–Business Solutions (800.800.5555) is a rapid-response provider of IT products and services serving primarily the small-and medium-sized business sector. It offers more than 425,000 brand-name products through its staff of technically trained sales account managers, publications, and its website at www.connection.com.

Connection–Enterprise Solutions (561.237.3300), www.connection.com/enterprise, provides corporate technology buyers with best-in-class IT solutions, in-depth IT supply-chain expertise, and access to over 425,000 products and 1,600 vendors through TRAXX™, a proprietary cloud-based eProcurement system. The team’s engineers, software licensing specialists, and project managers help reduce the cost and complexity of buying hardware, software, and services throughout the entire IT lifecycle.

Connection–Public Sector Solutions (800.800.0019), is a rapid-response provider of IT products and services to federal, state, and local government agencies and educational institutions through specialized account managers, publications, and online at www.connection.com/publicsector.

###

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005641/en/

Corporate Communications Contact:

Lynn MacKenzie, 603.683.2278

[email protected]

Investor Relations Contact:

Thomas Baker, 603.683.2505

Senior Vice President, CFO, and Treasurer

[email protected]

KEYWORDS: New Hampshire United States North America

INDUSTRY KEYWORDS: Technology Semiconductor Security Software Networks Internet Hardware Data Management Consumer Electronics

MEDIA:

Logo

BlackSky Reports Strong First Half Performance

Business Combination Remains on Track to Close During the Third Quarter of 2021

HERNDON, Va.–(BUSINESS WIRE)–
BlackSky Holdings, Inc. (“​BlackSky​”), a leading provider of real-time geospatial intelligence and global monitoring services, today provided a business update on its constellation growth, customer growth and revenue outlook.

BlackSky announced today that it remains on track to close the recently announced SPAC transaction with Osprey Technology Acquisition Corp. (“Osprey”) (NYSE: SFTW) during the third quarter of 2021. In addition, BlackSky continues strong execution of its business plan and is providing an update on key year to date operational highlights.

Constellation Deployment Accelerated

BlackSky continues to make significant strides in expanding its satellite constellation and image capture capacity over the first six months of this year and expects to achieve a 14-smallsat constellation by the end of 2021. The Company currently has six satellites providing imagery and information to its customers worldwide and has plans to launch eight more satellites prior to year-end, which would put BlackSky ahead of its planned eight operating satellites as announced in February, despite having lost two satellites due to a recent third-party launch failure. With these planned launches, BlackSky also remains on track to have a constellation of 23 high-resolution satellites by the end of 2023, capable of monitoring the most important locations on Earth every 60 minutes from dawn to dusk.

Expansion of Global Sales Force and Sales Pipeline Growth

The Company announced that during the first half of the year it has commenced several initiatives to accelerate its go-to-market plan. These initiatives include:

• Expansion of its International sales force and the creation of a UK office to address growing international opportunities.
• Expansion of the commercial sales force to accelerate the company’s commercial sector go-to-market plan, which is experiencing growing demand. During the last several months there has been a dramatic increase in commercial sales opportunities, and BlackSky is now engaged with more than 30 enterprises across a range of industries on how Spectra, its subscription-based global monitoring platform, can meet their business needs.
• Launch of a Global Reseller Program. The company established a formal global reseller program with 12 resellers on board with plans to expand the network to 24 by the end of 2021.

With these combined developments, BlackSky has more than doubled its sales force and has increased its pipeline of sales opportunities, with potential five-year estimated revenue ranging from $1.7 billion to $2.5 billion.

Strong Demand from Global Defense and Intelligence Agencies

BlackSky also announced that the National Reconnaissance Office’s (NRO) follow on to EnhancedView, the EO Commercial Layer program, appears to be back on track after a six-month pause. BlackSky is encouraged from recent events that the Request for Proposal (RFP) process is ramping back up and moving forward. Internationally, BlackSky is also announcing that it has signed a multi-year contract with a major international customer. The budget for that program is in place and the contract is moving forward. This is BlackSky’s largest international contract to date. The program was expected to commence in the third quarter, but after some delays on the customer end, is now expected to commence in the fourth quarter of 2021.

Updated 2021 and Future Year Revenue Outlook

BlackSky remains on track to nearly double revenues in 2021 and more than double revenues again in 2022 to approximately $114 million. The confidence in this growth was buoyed by the significant progress with defense and intelligence agencies and commercial customers during the first half of 2021. As a result of the six-month delay in the NRO program and the one quarter slip in the start of the international program, the company expects a $6 million impact to 2021 revenues. BlackSky is adjusting its 2021 revenue forecast to $40 million. The delay of the revenue contributions from these contracts is expected to be offset by increased revenues from new customers and the growth of existing customer relationships in 2022, and therefore BlackSky is making no change to its revenue forecasts for 2022 and beyond.

“We are pleased with the high commercial demand we are experiencing, the strong interest from global defense and intelligence agencies, and our ongoing relationship with the NRO, despite a couple of contract start delays. With the recently received NRO draft RFP in hand and a target commencement date for the international customer, we remain confident with our revenue forecasts for 2022 and beyond,” said Brian O’Toole, BlackSky’s CEO.

Business Combination Remains on Track

On February 18, 2021, BlackSky entered into a business combination agreement with Osprey Technology Acquisition Corp. The business combination is expected to close in the third quarter of 2021. Upon closing of the transaction, it is anticipated that BlackSky will be a publicly listed company and BlackSky’s existing management team will continue to lead the business.

“BlackSky is expanding and scaling through a regular cadence of launches and business growth,” added Mr. O’Toole. “We are consistently increasing our space and Spectra AI machine learning capabilities to deliver first-to-know insights for our customers. Since announcing our plan to go public, we have streamlined our ability to rapidly grow our space sensor network, accelerating our ability to deliver real-time intelligence with average one-hour, dawn-to-dusk imaging revisit rates and average 60-minute delivery times by the end of 2023,” added Mr. O’Toole. “We are pleased that the Osprey merger remains on track, as this transaction fully funds our growth plan and enables us to continue to invest in our delivery infrastructure and accelerate our go-to-market plan to reach new customers. There is significant pent-up demand in the market for affordable, easy access to real-time geospatial intelligence. As the industry shifts from static to real-time insights we are excited to provide the first-to-know insights about the things that matter most to our customers.”

About BlackSky Holdings, Inc.

BlackSky is a leading provider of real-time geospatial intelligence and global monitoring services. BlackSky monitors activities and facilities worldwide by harnessing the world’s emerging sensor networks and leveraging its own satellite constellation. BlackSky processes millions of data elements daily from its constellation as well as a variety of space, IoT, and terrestrial based sensors and data feeds. BlackSky’s on-demand constellation of satellites can image a location multiple times throughout the day. BlackSky monitors for pattern-of-life anomalies to produce alerts and enhance situational awareness. BlackSky’s monitoring service, Spectra AI, is powered by cutting-edge compute techniques including machine learning, artificial intelligence, computer vision, and natural language processing. BlackSky’s global monitoring solution is available via a simple subscription and requires no IT infrastructure or setup. On February 17, 2021, BlackSky entered into a definitive agreement for a business combination (the “Merger Agreement”) with Osprey (NYSE: SFTW) that would result in BlackSky becoming a publicly listed company. For more information visit www.blacksky.com.

About Osprey

Osprey is a special purpose acquisition company, or SPAC, that was established as a collaboration between investment firms HEPCO Capital Management, led by Jonathan and Edward Cohen, and JANA Partners, led by Barry Rosenstein and with its SPAC initiative led by JANA Partner David DiDomenico, who serves as Osprey’s CEO, President, and Director. Osprey was formed to consummate a transaction with one or more transformative companies that have developed innovative software delivery platforms. For more information visit www.osprey-technology.com.

Cautionary Statement Regarding Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transactions between Osprey and BlackSky. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transactions may not be completed in a timely manner or at all, which may adversely affect the price of Osprey’s securities, (ii) the risk that the transactions may not be completed by Osprey’s Business Combination deadline and the potential failure to obtain an extension of the Business Combination deadline if sought by Osprey, (iii) the failure to satisfy the conditions to the consummation of the transactions, including the adoption of the Merger Agreement by the stockholders of Osprey, the satisfaction of the minimum trust account amount following redemptions by Osprey’s public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third-party valuation in determining whether or not to pursue the proposed transactions, (v) the inability to complete the PIPE Investment, (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (vii) the effect of the announcement or pendency of the transactions on BlackSky’s business relationships, operating results, and business generally, (viii) risks that the proposed transactions disrupt current plans and operations of BlackSky, (ix) the outcome of any legal proceedings that may be instituted against BlackSky or against the Osprey related to the Merger Agreement or the proposed transactions, (x) the ability to maintain the listing of Osprey’s securities on a national securities exchange, (xi) changes in the competitive and regulated industries in which BlackSky operates, variations in operating performance across competitors, changes in laws and regulations affecting BlackSky’s business and changes in the combined capital structure, (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transactions, and identify and realize additional opportunities (xiii) the performance of our third-party service providers, including our satellite manufacturer and launch providers, (xiv) risks related to delays or cancellations from current or expected customers, (xv) the risk that redemptions by Osprey’s public stockholders may require the combined company to seek additional equity and/or debt financing to fund its business plan, and (xvi) the effects of natural disasters, terrorist attacks and the spread and/or abatement of infectious diseases, such as COVID-19, on the proposed transactions or on the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transactions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Osprey’s registration on Form S-1 (File No. 333-234180), the registration statement on Form S-4 discussed below and other documents filed by Osprey from time to time with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Osprey and BlackSky assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Osprey nor BlackSky gives any assurance that either Osprey or BlackSky, or the combined company, will achieve its expectations.

Additional Information and Where to Find It

This document relates to the proposed transactions between Osprey and BlackSky. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. On May 13, 2021, Osprey filed a registration statement on Form S-4 with the SEC, which included a document that serves as a prospectus and proxy statement of Osprey, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all Osprey stockholders. Osprey also will file other documents regarding the proposed transactions with the SEC. Before making any voting or investment decision, investors and security holders of Osprey are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transactions as they become available because they will contain important information about the proposed transactions.

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Osprey through the website maintained by the SEC at www.sec.gov.

The documents filed by Osprey with the SEC also may be obtained free of charge at Osprey’s website at https://www.osprey-technology.com or from Osprey upon written request to 1845 Walnut Street, Suite 1111, Philadelphia, Pennsylvania 19103.

Participants in Solicitation

Osprey and BlackSky and their directors and executive officers may be deemed to be participants in the solicitation of proxies from Osprey’s stockholders in connection with the proposed transactions. Osprey’s stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Osprey in Osprey’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2020, which was filed with the SEC on May 12, 2021, and in Osprey’s registration statement on Form S-4, which was filed by Osprey with the SEC in connection with the business combination on May 13, 2021. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Osprey’s stockholders in connection with the proposed business combination is set forth in the proxy statement/prospectus on Form S-4 for the proposed business combination, which was filed by Osprey with the SEC in connection with the business combination on May 13, 2021.

A list of the names of such directors and executive officers and information regarding their interests in the transactions are or will be contained in the proxy statement/prospectus. You may obtain free copies of these documents as described in the preceding paragraph.

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005627/en/

Investors

Michael Bowen and Ryan Gardella

BlackSkyIR​@icrinc.com

Media:

Colleen Moffitt

[email protected]

206-282-4923 ext. 113

206-979-4696

Phil Denning

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Data Management Satellite Technology Other Technology Software Networks Hardware

MEDIA:

Posted on June 8, 2021 7:07 am

908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors

908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer of Labcorp Diagnostics, to its Board of Directors

Third Board appointment of 2021 supports long-term vision for the company’s technology platform

BOSTON–(BUSINESS WIRE)–908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, to serve on its Board of Directors effective immediately.

Dr. Eisenberg has extensive experience with forensic DNA testing, biotechnology, molecular genetics and molecular oncology. She has helped lead the development and validation of well over a thousand clinical assays used for patient care during her more than 30-year tenure at Labcorp (NYSE: LH), a global life sciences company. Dr. Eisenberg previously held roles on the National Institute of Environmental Health Sciences and the FBI’s National DNA Advisory Board, where she was later recognized for her contributions to the advancement of DNA technology. Earlier this year, Dr. Eisenberg was recognized by the Healthcare Businesswomen’s Association (HBA) as a 2021 Luminary.

“I have had the opportunity to know and work with Marcia for well over a decade, and I have always been impressed with her ability to transform science into viable diagnostic assays,” said Kevin Hrusovsky, chairman of 908 Devices. “Marcia has a proven track record and a broad range of experience from diagnostics, to drug development and to forensics. Her unique perspective will be an important addition to our Board. I look forward to collaborating with Marcia as we support 908 Devices in executing on its vision to democratize mass spectrometry.”

Dr. Eisenberg’s appointment comes on the heels of two additions to the Board earlier this year: Jeff George and Fenel Eloi.

“908 Devices is guided by an amazing group of Board members with talents spanning technology and applications, finance and operations, and we are fortunate to have such a wealth of experience to draw upon,” said Kevin J. Knopp, CEO and co-founder of 908 Devices. “Marcia’s appointment supports our efforts of today, but also our long-term, visionary platform aspirations in proteomics and diagnostics. I am very excited that she has joined us on our journey.”

To learn more about 908 Devices, please visit 908devices.com.

About 908 Devices

908 Devices (NASDAQ: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics, and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements,” including with respect to the composition of the Company’s Board of Directors. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the SEC which are available on the SEC’s website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005457/en/

Media

Katie Johnston

PAN Communications for 908 Devices

[email protected]

Investor

Carrie Mendivil

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Consumer Electronics Technology Health Other Science Other Technology Medical Devices Research Software Science Hardware

MEDIA:

Logo

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

Company to Hold Fiscal Fourth Quarter and Fiscal Year 2021 Earnings Conference Call and Virtual Investor and Technology Day on July 13, 2021

LATHAM, N.Y.–(BUSINESS WIRE)–
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature.

AngioDynamics continues to anticipate the commercial release of the AlphaVac System in the second half of calendar year 2021.

The Company will report financial results for the fourth quarter and fiscal year 2021 before the market open on Tuesday, July 13, 2021. The Company’s management will host a conference call at 8:00 a.m. ET to discuss the results.

Management will also host a virtual Investor and Technology Day following its earnings conference call at 9:30 a.m. ET that same day.

Further details, including registration, webcast, and dial-in information, will be provided at a later date.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.

AngioDynamics and AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005400/en/

Investor Relations:

AngioDynamics, Inc.

Stephen Trowbridge

518-795-1408

[email protected]

Media:

AngioDynamics, Inc.

Saleem Cheeks

518-795-1174

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Surgery Medical Devices Health Cardiology Oncology

MEDIA:

Logo

Tilray Announces Launch of New Medical Cannabis Brand, Symbios

— Inaugural Brand From the “new” Tilray Provides a Broader Spectrum of Formats and Cannabinoid Ratios at a Better Price Point —

NEW YORK & LEAMINGTON, Ontario–(BUSINESS WIRE)–
Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the launch of Symbios, a complement to the Company’s existing medical brand portfolio in Canada. This new brand was developed to provide a broader spectrum of formats and unique cannabinoid ratios at a better price point while offering medical patients a full comprehensive assortment of products, including flower, oils, and pre-rolls for their health and wellness regiment.

Irwin D. Simon, Tilray’s Chief Executive Officer, said, “Medical cannabis innovation and patient care are core to the new Tilray’s business and global growth strategy. As we look ahead, we remain focused on building momentum across our three medical brands – Symbios, Aphria, and Tilray — while meeting the large and growing demand for new, high-quality cannabis products that promote health, wellness, and wellbeing.”

Contemporaneous with today’s announcement, Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin¹. They are made from a vegan and cruelty-free cream formulation and include CBD 750 (containing 750mg of CBD) and Balance 750 (containing 375mg of THC and 375mg of CBD).

Jim Meiers, President, Tilray Canada, added, “Symbios and our new Aphria topical treatments are exciting new additions to our medical portfolio in Canada, providing our patients with a broader selection of unique product formats to meet their needs and preferences. Our industry is only in the early stages of creating and bringing to market cannabinoid medicine options that meet patient needs. We are committed to building our leadership position in Canada now and into the future.”

Symbios and Aphria’s new high-potency topicals join a range of other products, including cannabis oils, soft gels, oral sprays, whole dried flower, and vapes that are now available to all medical patients through the Aphria online medical patient portal.

For more information about Symbios and Aphria medical cannabis products, visit: www.Aphria.ca

About Aphria, Tilray’s Medical Cannabis Brand

Aphria started in 2014 in Leamington, Ontario, as one of the first companies to provide access to legal, medical cannabis. Since then, the Aphria brand has grown to be one of the top medical cannabis providers globally, with operations in Canada and international markets. Aphria remains committed to supplying its growing patient base with safe, affordable, consistent, and effective medical cannabis products.

About Tilray

Tilray, Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.

For more information about Tilray, Inc., visit: www.Tilray.com

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

---

¹ Philpott, Holly T., et al. “Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.” Pain. 2017 Dec; 158(12). DOI: 10.1097/j.pain.0000000000001052

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005394/en/

For media inquiries, please contact:

Berrin Noorata

[email protected]

For investor inquiries, please contact:

Raphael Gross

203-682-8253

[email protected]

KEYWORDS: United States North America Canada New York

INDUSTRY KEYWORDS: Alternative Medicine Other Retail Wine & Spirits General Health Health Food/Beverage Fitness & Nutrition Retail

MEDIA:

Posted on June 8, 2021 7:06 am

Spire Global Appoints Head of Communications

Spire Global Appoints Head of Communications

Hillary Yaffe to Lead Spire’s Corporate Communications and Investor Relations Strategy Worldwide

VIENNA, Va. & RESTON, Va.–(BUSINESS WIRE)–
Today Spire Global, Inc. (“Spire” or the “Company”), a space-based Earth data analytics and solutions company, announced that it has appointed Hillary Yaffe as Head of Communications, effective June 1, 2021. Ms. Yaffe will report to Peter Platzer, Founder and Chief Executive Officer of Spire, and will be based in New York.

In her new role, Ms. Yaffe will oversee Spire’s corporate communications and investor relations engagement worldwide as well as Spire’s communications strategy across the Company’s key business units, including Maritime, Weather, Aviation, Space Services, Federal, and Earth Intelligence. She will additionally guide Spire’s engagement with the investor community as the Company works to complete its previously announced merger with NavSight Holdings, Inc. (NYSE: NSH) to become a publicly traded company.

“We are thrilled to welcome a communications industry veteran of Hillary’s caliber to the Spire team at this watershed moment for our company,” said Mr. Platzer. “Hillary’s communications expertise across multiple industries, and specifically the capital markets, will prove invaluable as we look to convey Spire’s business plan, strategic growth initiatives, and corporate values to all stakeholders, including investors, customers and the media.”

Ms. Yaffe most recently served as Senior Vice President and Head of Communications for Lazard Asset Management LLC (“Lazard”) in the United States, where she was responsible for both internal and external communications activity. Prior to joining Lazard, Ms. Yaffe served as an Associate Vice President at Prosek Partners, where she helped build out the firm’s hedge fund practice and advised large institutional investment firms. Ms. Yaffe began her career at Edelman and subsequently worked at Burson-Marsteller in their corporate/financial practice before joining Prosek Partners. Ms. Yaffe holds a BBA in International Business and Marketing from The George Washington University.

About Spire Global, Inc.

Spire is a global provider of space-based data and analytics that offers unique datasets and powerful insights about Earth from the ultimate vantage point so organizations can make decisions with confidence, accuracy, and speed. Spire uses one of the world’s largest multi-purpose satellite constellations to source hard to acquire, valuable data and enriches it with predictive solutions. Spire then provides this data as a subscription to organizations around the world so they can improve business operations, decrease their environmental footprint, deploy resources for growth and competitive advantage, and mitigate risk. Spire gives commercial and government organizations the competitive advantage they seek to innovate and solve some of the world’s toughest problems with insights from space. Spire has offices in San Francisco, CA, Boulder, CO, Washington DC, Glasgow, Luxembourg, and Singapore. On March 1, 2021 Spire announced plans to go public through an anticipated business combination with NavSight Holdings, Inc. (NYSE: NSH), to be traded on the NYSE under the ticker symbol “SPIR.” To learn more, visit spire.com.

About NavSight Holdings, Inc.

NavSight Holdings, Inc. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. NavSight was organized with the opportunity to pursue a business combination target in any business or industry, with the intent to focus its search on identifying a prospective target business that provides expertise and technology to U.S. government customers in support of their national security, intelligence and defense missions.

Additional Information and Where to Find It

In connection with the planned business combination with Spire (the “Proposed Transaction”), NavSight has filed a Form S-4 Registration Statement (the “Registration Statement”) with the SEC, which includes a preliminary proxy statement to be distributed to holders of NavSight’s common stock in connection with NavSight’s solicitation of proxies for the vote by NavSight’s stockholders with respect to the Proposed Transaction and other matters as described in the Registration Statement, a prospectus relating to the offer of the securities to be issued to the Company’s stockholders in connection with the Proposed Transaction, and an information statement to Company’s stockholders regarding the Proposed Transaction. After the Registration Statement is declared effective, NavSight will mail a definitive proxy statement/prospectus, when available, to its stockholders. Investors and security holders and other interested parties are urged to read the proxy statement/prospectus, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about NavSight, the Company and the Proposed Transaction. Investors and security holders may obtain free copies of the preliminary proxy statement/prospectus and definitive proxy statement/prospectus (when available) and other documents filed with the SEC by NavSight through the website maintained by the SEC at http://www.sec.gov, or by directing a request to: NavSight Holdings, Inc., 12020 Sunrise Valley Drive, Suite 100, Reston, VA 20191.

Participants in Solicitation

NavSight and the Company and their respective directors and certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies with respect to the Proposed Transaction. Information about the directors and executive officers of NavSight is set forth in its Form 10-K/A and Form 10-Q filed on May 12, 2021 and May 24, 2021, respectively. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is included in the Registration Statement and other relevant materials filed with the SEC regarding the Proposed Transaction. Stockholders, potential investors and other interested persons should read the Registration Statement carefully before making any voting or investment decisions. These documents can be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the federal securities laws with respect to the Proposed Transaction. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding expectations of corporate communications strategy and investor relations engagement across Spire and the applicability of such strategies and engagement to Spire’s market, expectations of accelerating Spire’s sales and marketing efforts, expectations of product development and the applicability of such products to Spire’s market, the strengthening of Spire’s competitive advantage, the importance of Spire’s products and capabilities to its target markets, the expansion of Spire’s business to new regions and markets, Spire’s future growth, estimates and forecasts of financial and performance metrics, expectations of achieving and maintaining profitability, projections of total addressable markets, market opportunity and market share, net proceeds from the Proposed Transactions, potential benefits of the Proposed Transaction and the potential success of the Company’s market and growth strategies, and expectations related to the terms and timing of the Proposed Transaction. These statements are based on various assumptions and on the current expectations of NavSight’s and the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of NavSight and the Company. These forward-looking statements are subject to a number of risks and uncertainties, including (i) the risk that the Proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of NavSight’s securities; (ii) the risk that the Proposed Transaction may not be completed by NavSight’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by NavSight; (iii) the failure to satisfy the conditions to the consummation of the Proposed Transaction, including the approval of the Proposed Transaction by the stockholders of NavSight, the satisfaction of the minimum trust account amount following any redemptions by NavSight’s public stockholders and the receipt of certain governmental and regulatory approvals; (iv) the inability to complete the PIPE investment in connection with the Proposed Transaction; (v) the failure to realize the anticipated benefits of the Proposed Transaction; (vi) the effect of the announcement or pendency of the Proposed Transaction on Spire’s business relationships, performance, and business generally; (vii) risks that the Proposed Transaction disrupts current plans of Spire and potential difficulties in Spire employee retention as a result of the Proposed Transaction; (viii) the outcome of any legal proceedings that may be instituted against NavSight or Spire related to the business combination agreement or the Proposed Transaction; (ix) the ability to maintain the listing of NavSight’s securities on the New York Stock Exchange; (x) the ability to address the market opportunity for Space-as-a-Service; (xi) the risk that the Proposed Transaction may not generate expected net proceeds to the combined company; (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the Proposed Transaction, and identify and realize additional opportunities; (xiii) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (xiv) the risk of downturns, new entrants and a changing regulatory landscape in the highly competitive space data analytics industry; and those factors discussed in NavSight’s Form S-4 filed on May 14, 2021 under the heading “Risk Factors,” and other documents of NavSight filed, or to be filed, with the SEC. If any of these risks materialize or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither NavSight nor the Company presently know or that NavSight and the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect NavSight’s and the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. NavSight and the Company anticipate that subsequent events and developments will cause NavSight’s and the Company’s assessments to change. However, while NavSight and the Company may elect to update these forward-looking statements at some point in the future, NavSight and the Company specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing NavSight’s and the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005343/en/

For Spire Global, Inc.:

Investor Contact:

Michael Bowen and Ryan Gardella

[email protected]

Media Contact:

Phil Denning

[email protected]

For NavSight Holdings, Inc.:

Investor Contact:

Jack Pearlstein

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Alternative Energy Security Aerospace Data Management Energy Satellite Manufacturing Technology Nanotechnology Public Relations/Investor Relations Finance Communications Professional Services Software Networks Engineering

MEDIA:

Posted on June 8, 2021 7:06 am

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

Foundation Medicine Launches FoundationOne^®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

Personalized technology aims to address both early- and advanced-stage cancer monitoring applications

CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine’s personalized circulating tumor DNA (ctDNA) monitoring assay. FoundationOne Tracker uniquely combines Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP) platform with Natera’s expertise in ctDNA monitoring.

FoundationOne Tracker uses optimized algorithms for identifying tumor-specific variants and a personalized assay design that allows for the detection of ctDNA in plasma for use in both advanced- and early-stage research applications. Additionally, the creation of a robust, fully integrated workflow between Foundation Medicine and Natera is expected to provide rapid inclusion of ctDNA monitoring results into retrospective research studies.

“The addition of FoundationOne Tracker for research use provides our biopharma and academic partners access to Foundation Medicine’s broad, advanced-stage CGP footprint,” said Foundation Medicine’s Chief Scientific Officer Priti Hegde. “In partnering with Natera, we have been able to leverage the best of both of our technologies to provide a cost-effective and efficient path to bring more personalized monitoring tools to our partners, and down the line, to physicians and patients, to help inform their treatment strategy.”

“This partnership will help accelerate personalized ctDNA monitoring as the new standard of care in oncology,” said Solomon Moshkevich, Natera’s general manager of oncology. “With Foundation Medicine’s strong track record of scientific leadership and its broad footprint within biopharma, we expect FoundationOne Tracker to become an important new tool for accelerating and improving drug development in oncology.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine®^{and FoundationOne® are registered trademarks of Foundation Medicine, Inc.}

About Natera

Natera is a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, our ability to successfully increase demand for and grow revenues for our product offerings, whether the results of clinical or other studies will support the use of our product offerings, our collaborations with commercial partners such as pharmaceutical companies, medical institutions, contract laboratories, laboratory partners, and other third parties, our ability to successfully execute the partnership and co-develop the assay, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Source: Foundation Medicine

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005248/en/

Foundation Medicine Contact:

Abigail Alderman, 781-534-3210

[email protected]

Natera Contacts:

Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090

Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 [email protected]

KEYWORDS: Texas Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo

Innovative Industrial Properties Publishes Inaugural Environmental, Social and Corporate Governance (ESG) Report

SAN DIEGO–(BUSINESS WIRE)–
Innovative Industrial Properties, Inc. (IIP), the first and only real estate company on the New York Stock Exchange (NYSE: IIPR) focused on the regulated U.S. cannabis industry, announced today that it has published its inaugural Environmental, Social and Governance (ESG) report. The report highlights how the company is addressing the top ESG priorities that matter to its stockholders, employees, tenant partners, communities and other stakeholders.

“The IIP team is excited to issue our first annual ESG report, demonstrating our commitment to sound environmental management, collaborative community engagement and strong corporate governance principles that align to our team’s core values,” said Alan Gold, Executive Chairman. “Our company, working closely with our long-term tenant partners, continues to drive substantial and lasting positive changes in the communities where we operate, by repositioning and renovating industrial buildings, bringing good long-term jobs to historically economically disadvantaged communities, and developing businesses that generate substantial tax revenues to support local services, schools and healthcare. Since beginning operations in December 2016, we are proud of what we have accomplished in these areas, as well as the contributions that our company and tenant partners have made across numerous other important causes. We are focused on continuing to make strong progress in our ESG goals, and look forward to providing all of our stakeholders annual updates on our achievements and future plans in these areas.”

Select highlights from IIP’s ESG report include:

• IIP invests extensively in economically disadvantaged communities, with direct employment at IIP’s properties alone supporting over 5,000 full time employment positions as of year-end 2020, which is in addition to the construction jobs and numerous ancillary jobs across a wide spectrum of specialties that support IIP’s tenant partners’ operations.

• Many of IIP’s projects focus on the redevelopment of existing industrial buildings, revitalizing previously vacant or under-utilized buildings, which translates into dramatic reductions of demolition and landfill disposal, driving embodied carbon savings.

• IIP partners with its tenants to extensively improve energy efficiency and environmental performance of its properties, including funding of improvements such as lighting upgrades, installation of building management systems, implementation of stormwater management systems, heating, ventilation and air conditioning upgrades, tiered cultivation, advanced irrigation systems, health and safety systems and greenhouse construction.

• IIP prioritizes the health and wellbeing of its employees, and moved all employees to a remote work environment in response to the COVID-19 pandemic, while at the same time working to foster connection and appreciation throughout this time.

• IIP established a Diversity, Equality & Inclusion Policy, Human Rights Policy and Vendor Code of Conduct, which reflect IIP’s core values in these areas.

• IIP and its tenant partners, as well as IIP’s individual employees and board members, extensively donated their time, expertise and financial resources across a wide spectrum of social initiatives, with that need being even more pressing in the face of challenges presented by the COVID-19 pandemic.

IIP’s 2021 ESG report is available on its corporate website at www.innovativeindustrialproperties.com/ESG/.

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities. Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017. Additional information is available at www.innovativeindustrialproperties.com.

Innovative Industrial Properties Forward-Looking Statements

This press release contains statements that IIP believes to be “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements. When used in this press release, words such as we “expect,” “intend,” “plan,” “estimate,” “anticipate,” “believe” or “should” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. IIP disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005206/en/

IIP Contact:

Catherine Hastings

Chief Financial Officer

Innovative Industrial Properties, Inc.

(858) 997-3332

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Alternative Medicine Environment Health Tobacco REIT Retail

MEDIA:

Logo

Tuscan Holdings Corp. Files Revised Preliminary Proxy Statement, Sets Record Date for Stockholders Eligible to Vote on Business Combination

Stockholder vote expected to be on or about July 16, 2021

NEW YORK–(BUSINESS WIRE)–
Tuscan Holdings Corp. (Nasdaq: THCB) (“Tuscan Holdings”) announced today that it filed a revised preliminary proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with the proposed business combination with Microvast, Inc., a leading global provider of next-generation battery technologies for commercial and specialty vehicles. The Company set the close of business on June 21, 2021 as the record date for the determination of stockholders eligible to vote at its special meeting of stockholders (the “Special Meeting”). Tuscan Holdings expects the Special Meeting to be held on or about July 16, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005286/en/

The consummation of the proposed business combination with Microvast and related items requires approval at the Special Meeting by the affirmative vote of the holders of over 50% of the outstanding Tuscan shares. Only stockholders who hold Tuscan shares on June 21, 2021 will be eligible to vote at the Special Meeting.

The previously announced business combination is expected to provide $822 million of gross proceeds to Microvast. PIPE anchor investors include strategic partner Oshkosh Corporation as well as funds and accounts managed by BlackRock, Koch Strategic Platforms and InterPrivate. Upon the closing of the business combination, the combined company will be named Microvast Holdings, Inc. and is expected to be listed on the Nasdaq Stock Market under the new ticker symbol “MVST.”

The revised preliminary proxy statement is subject to SEC review and stockholders are not required to take any action at this time. Once final, a definitive proxy statement will be mailed together with a proxy card to Tuscan Holdings’ stockholders who hold shares on June 21, 2021. The definitive proxy statement will include the date and time of the Special Meeting.

About Microvast

Microvast, Inc. is a technology innovator that designs, develops and manufactures lithium-ion battery solutions. Founded in 2006 and headquartered in Houston, TX, Microvast is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry (cathode, anode, electrolyte, and separator) to battery packs. By integrating the process from raw material to system assembly, Microvast has developed a family of products covering a broad breadth of market applications. More information can be found on the corporate website: www.microvast.com.

About Tuscan

Tuscan Holdings Corp. is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Tuscan’s management team is led by Stephen Vogel, Chairman and Chief Executive Officer. Tuscan is listed on Nasdaq under the ticker symbol “THCB.”

About InterPrivate

InterPrivate Capital is a private investment firm that invests on behalf of a consortium of family offices. The firm’s unique independent co-sponsor structure provides its investors with the deep sector expertise and transaction execution capabilities of veteran deal-makers from the world’s leading private equity and venture capital firms. Affiliates of InterPrivate Capital act as sponsors, co-sponsors and advisors of SPACs, and manage a number of investment vehicles on behalf of its family office co-investors that participate in private and public opportunities, including PIPE investments in support of the firm’s sponsored business combinations. For more information regarding InterPrivate Capital, please visit www.interprivate.com. For more information regarding InterPrivate’s SPAC strategy, please visit www.ipvspac.com.

Additional Information and Where to Find It

In connection with the proposed transaction (the “Proposed Transaction”) involving Tuscan and Microvast, Tuscan intends to file relevant materials with the SEC, including a definitive proxy statement (“Merger Proxy Statement“). On June 3, 2021 Tuscan filed a revised preliminary proxy statement with the SEC relating to the Proposed Transaction. INVESTORS AND SECURITY HOLDERS AND OTHER INTERESTED PARTIES ARE URGED TO READ THE MERGER PROXY STATEMENT FOR MORE INFORMATION ABOUT THE PROPOSED TRANSACTION WITH MICROVAST, AND TO READ ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE. The Merger Proxy Statement and other documents that may be filed with the SEC (when they are available) can be obtained free of charge from the SEC’s website at www.sec.gov. These documents (when they are available) can also be obtained free of charge from Tuscan upon written request to Tuscan at Tuscan Holdings Corp., 135 E. 57th St., 17th Floor, New York, NY 10022.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and shall not constitute a proxy statement or the solicitation of a proxy, consent or authorization with respect to any securities in respect of the Proposed Transaction and shall not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote of approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Participants in Solicitation

This communication is not a solicitation of a proxy from any investor or securityholder. However, Tuscan and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the Proposed Transaction under the rules of the SEC. Information about Tuscan’s directors and executive officers and their ownership of Tuscan’s securities is set forth in Tuscan’s filings with the SEC, including Tuscan’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 25, 2021. To the extent that holdings of Tuscan’s securities have changed since the amounts included in Tuscan’s Annual Report, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the participants is also included in the preliminary proxy statement filed on June 3, 2021 and will be included in the definitive Merger Proxy Statement, when it becomes available. When available, these documents can be obtained free of charge from the sources indicated above. Additional information is also included in the definitive proxy statement which was filed with the SEC on March 24, 2021 and mailed to Tuscan’s stockholders on or about March 25, 2021.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. These forward-looking statements include, but are not limited to, statements regarding the expected proceeds from the Proposed Transaction, the timing of the Special Meetingand the likelihood and ability of the parties to successfully consummate the Proposed Transaction. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

In addition to factors previously disclosed in Tuscan’s reports filed with the SEC and those identified elsewhere in this communication, the following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: (1) a delay in the timing of the Special Meeting due to, among other things, the timing of the completion of the SEC review process; (2) the inability to complete the Proposed Transaction or, if Tuscan does not complete the Proposed Transaction, any other business combination; (3) the inability to complete the Proposed Transaction due to the failure to meet the closing conditions to the Proposed Transaction, including the inability to obtain approval of Tuscan’s stockholders, the inability to consummate the contemplated PIPE financing, the failure to achieve the minimum amount of cash available following any redemptions by Tuscan stockholders, the failure to meet the Nasdaq listing standards in connection with the consummation of the Proposed Transaction, or the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement; (4) costs related to the Proposed Transaction; (5) a delay or failure to realize the expected benefits from the Proposed Transaction; (6) risks related to disruption of management time from ongoing business operations due to the Proposed Transaction; (7) the impact of the ongoing COVID-19 pandemic; (8) changes in the highly competitive market in which Microvast competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (9) changes in the markets that Microvast targets; (10) risk that Microvast may not be able to execute its growth strategies or achieve profitability; (11) the risk that Microvast is unable to secure or protect its intellectual property; (12) the risk that Microvast’s customers or third-party suppliers are unable to meet their obligations fully or in a timely manner; (13) the risk that Microvast’s customers will adjust, cancel, or suspend their orders for Microvast’s products; (14) the risk that Microvast will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (15) the risk of product liability or regulatory lawsuits or proceedings relating to Microvast’s products or services; (16) the risk that Microvast may not be able to develop and maintain effective internal controls; (17) the outcome of any legal proceedings that may be instituted against Tuscan, Microvast or any of their respective directors or officers following the announcement of the Proposed Combination; (18) risks of operations in the People’s Republic of China; and (19) the failure to realize anticipated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions and purchase price and other adjustments.

Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about Tuscan and Microvast or the date of such information in the case of information from persons other than Tuscan or Microvast, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding Microvast’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purpose only, are not forecasts and may not reflect actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005286/en/

Microvast Investor Relations

[email protected]

(346) 309-2562

Microvast Public Relations

[email protected]

Tuscan Holdings Corp.

Investor Relations, ICR

[email protected]

InterPrivate Capital

Charlotte Luer

Investor Relations

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Automotive Other Energy Alternative Vehicles/Fuels Energy Finance

MEDIA:

Logo

Logo

Logo